Approved more than two decades ago and generating roughly $20 billion in sales, Tamiflu never underwent rigorous randomized trials in the sickest patients.
A new HHS investigation finds tens of millions of dollars in puberty-blocker claims billed under vague, unrecognizable diagnostic codes at hospitals nationwide.
What happens to patients who detransition? A pediatrician, bioethics advocate, and a real detransitioner examine the medical, psychological, and legal realities the system isn't prepared for.

